Abstract:Objective: To observe the clinical efficacy and safety of apatinib in the maintenance treatment of platinum-resistant recurrent ovarian cancer after second-line chemotherapy. Methods: This study collected 36 patients diagnosed with platinum-resistant recurrent ovarian cancer, and who had received at least 4 courses of non-platinum second-line chemotherapy and had achieved clinical remission or stabilization. Then they were given apatinib with initial dose of 500 mg every day for maintenance treatment until disease progressed or toxic side effects were intolerable. In combination with the response evaluation criteria in solid tumors (RECIST) 1.0 and CA125 and HE4 two measures as the synthesis evaluation of curative effect, according to the National Cancer Institute (NCI) of the common toxic standard version 3.0 of BEV, the paclitaxel and platinum drug adverse reaction of chemotherapy were graded. Results: The objective response rate (ORR) of 36 patients was 52.2%, and the disease control rate (DCR) was 69.4%. Among 19 patients who achieved partial remission, the median duration of remission was 8.1 months (2.5-23.1), of which 12 patients (63.2%) had a remission duration equal to or greater than 6 months. Among the 6 patients with stable disease evaluation, the median stable duration was 5.85 months, and 3 patients had stable disease duration of 6 months or longer. Patients who orally took apatinib 250 mg daily could be well tolerated. Conclusion: Apatinib in the maintenance treatment of platinum-resistant recurrent ovarian cancer after second-line chemotherapy is safe and effective.
